Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) Short Interest Update

Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) was the recipient of a large decrease in short interest during the month of August. As of August 31st, there was short interest totaling 18,067 shares, a decrease of 65.5% from the August 15th total of 52,394 shares. Based on an average daily trading volume, of 69,889 shares, the short-interest ratio is presently 0.3 days. Approximately 0.6% of the shares of the company are short sold.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cyclerion Therapeutics in a report on Friday, July 24th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company has a consensus rating of “Sell”.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of CYCN. ADAR1 Capital Management LLC purchased a new position in Cyclerion Therapeutics during the second quarter valued at approximately $1,013,000. Braidwell LP purchased a new stake in Cyclerion Therapeutics during the second quarter worth $532,000. BlackRock Inc. bought a new stake in Cyclerion Therapeutics during the 2nd quarter valued at $57,000. Finally, Two Sigma Investments LP bought a new stake in Cyclerion Therapeutics during the 3rd quarter valued at $31,000. Institutional investors own 75.62% of the company’s stock.

Cyclerion Therapeutics Stock Performance

The business’s fifty day moving average price is $25.14 and its 200-day moving average price is $21.35. Cyclerion Therapeutics has a 1-year low of $1.03 and a 1-year high of $8.48. The stock has a market capitalization of $16.33 million, a price-to-earnings ratio of -2.10 and a beta of 1.75.

About Cyclerion Therapeutics

Cyclerion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of inhibitors and stimulators of soluble guanylate cyclase (sGC), an intracellular enzyme that plays a critical role in the regulation of vascular tone, cellular proliferation and inflammation. By targeting the nitric oxide (NO)–sGC–cyclic guanosine monophosphate (cGMP) signaling pathway, Cyclerion aims to address a range of cardiometabolic, cardiovascular, pulmonary and neurological disorders with significant unmet medical need.

The company’s lead program, praliciguat, is an oral sGC stimulator investigated for indications such as diabetic nephropathy, metabolic syndrome and heart failure with preserved ejection fraction.